Introducing neurofilament light chain measure in psychiatry: current evidence, opportunities, and pitfalls
Francesco Bavato(University of Zurich), Boris B. Quednow(University Hospital of Zurich), Christian Barro(Brigham and Women's Hospital), Erich Seifritz(University of Zurich), Joel Simrén(University of Gothenburg), Laura K. Schnider(University of Zurich), Henrik Zetterberg(University of Wisconsin–Madison)
Cited by 81
Related Papers
Defeating Alzheimer's disease and other dementias: a priority for European science and society
|The Lancet Neurology|2016|1.7k
Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease
|Nature Medicine|2019|948
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum
|JAMA Neurology|2021|627
Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report
|Nature Medicine|2019|606
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease
|Alzheimer s & Dementia|2022|589